Overview:

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global Clinical Trial Supplies Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The market size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Market Size Estimation:

The global size of the clinical trial supplies market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and market have been identified through extensive secondary research.
# The revenues generated from the clinical trial supplies business of leading players have been determined through primary and secondary research.
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation:

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=172240059

Projected Revenue Surge:

The global clinical trial supplies market is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2021, at a CAGR of 8.5% during the forecast period of 2021 to 2026.

DRIVER: Increasing RD expenditure of pharmaceutical and biopharmaceutical companies

The pharmaceutical and biopharmaceutical sector is one of the biggest RD spenders globally. In the last decade, the RD expenditure of pharmaceutical and biopharmaceutical companies has risen considerably. This is expected to lead to a rise in the number of clinical trials conducted globally. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), PhRMA members have invested significantly in drug development efforts. Companies in the market are actively looking to support RD efforts. A further increase in RD spending in the coming years will significantly boost drug discovery and development activities, thus driving the demand for clinical trial supplies.

RESTRAINTS: High cost of drug development

Drug discovery and development involve high costs due to the high attrition rate of drug candidates in development. Since RD for some rare diseases is very challenging and requires a specific group of people to conduct a clinical trial, drug RD processes can be prone to failure.

Only 7 out of 100 cancer drugs that reach the clinical testing phase end up gaining regulatory approval; most drugs fail long before this point. From drug discovery through FDA approval, developing a new medicine, on average, takes 10–15 years and costs USD 2.6 billion. Less than 12% of candidates that make it to Phase I clinical trials are approved by the FDA. This is a key factor limiting the growth of the market.

Recent Developments:

# In April 2021, Thermo Fisher announced plans to acquire PPD for USD 17.4 billion to enhance its offerings in clinical research services and to support clinical trials.

# In April 2021, Parexel collaborated with Veeva Systems to improve their clinical processes for clinical trial delivery and enhance Veeva’s cloud technology.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=172240059

The pharmaceutical and biotechnology companies segment accounted for the largest share in 2020

Based on end users, the clinical trial supplies market is categorized into three segments—pharmaceutical biotechnology companies, contract research organizations (CROs), and medical device companies. The pharmaceutical and biotechnology companies accounted for the largest share of 70% of this market in 2020. This share is attributed to the rising RD efforts by these companies.

North America was the largest regional market for clinical trial supplies in 2020.

Geographically, the market is segmented into North America, Europe, Asia Pacific, RoW. In 2020, North America accounted for the largest share of the clinical trial supplies market, followed by Europe Asia Pacific. The growing number of registered clinical trials and significant investments in RD for clinical trials in this region are major factors driving the growth of the North American market. The presence of many global pharmaceutical giants, such as Pfizer, Abbott Laboratories, and Johnson Johnson (which outsource their clinical trials to reduce the costs and time associated with completing these trials) in this region is another key driver for market growth.